dostęp otwarty

Tom 14, Nr 6 (2017)
Nadciśnienie tętnicze
Pobierz cytowanie

Kompleksowe leczenie chorych z nadciśnieniem tętniczym — nie tylko redukcja ciśnienia tętniczego

Stefan Grajek
Choroby Serca i Naczyń 2017;14(6):305-314.

dostęp otwarty

Tom 14, Nr 6 (2017)
Nadciśnienie tętnicze

Streszczenie

Hipercholesterolemia i nadciśnienie tętnicze są uznanymi czynnikami ryzyka choroby niedokrwiennej serca. Skojarzone leczenie statyną, inhibitorem konwertazy angiotensyny i antagonistą wapnia u chorych z nadciśnieniem tętniczym redukuje częstość występowania poważnych zdarzeń sercowo-naczyniowych. Leczenie skojarzone jest skuteczniejsze od samej terapii hipotensyjnej. Preparaty złożone, zwiększając współpracę pacjenta, mogą być skuteczną metodą leczenia chorych obciążonych wieloma czynnikami ryzyka.

Streszczenie

Hipercholesterolemia i nadciśnienie tętnicze są uznanymi czynnikami ryzyka choroby niedokrwiennej serca. Skojarzone leczenie statyną, inhibitorem konwertazy angiotensyny i antagonistą wapnia u chorych z nadciśnieniem tętniczym redukuje częstość występowania poważnych zdarzeń sercowo-naczyniowych. Leczenie skojarzone jest skuteczniejsze od samej terapii hipotensyjnej. Preparaty złożone, zwiększając współpracę pacjenta, mogą być skuteczną metodą leczenia chorych obciążonych wieloma czynnikami ryzyka.
Pobierz cytowanie

Słowa kluczowe

nadciśnienie tętnicze, hiperlipidemia, globalne ryzyko sercowo-naczyniowe, pojedyncza tabletka

Informacje o artykule
Tytuł

Kompleksowe leczenie chorych z nadciśnieniem tętniczym — nie tylko redukcja ciśnienia tętniczego

Czasopismo

Choroby Serca i Naczyń

Numer

Tom 14, Nr 6 (2017)

Strony

305-314

Rekord bibliograficzny

Choroby Serca i Naczyń 2017;14(6):305-314.

Słowa kluczowe

nadciśnienie tętnicze
hiperlipidemia
globalne ryzyko sercowo-naczyniowe
pojedyncza tabletka

Autorzy

Stefan Grajek

Referencje (56)
  1. Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213–223.
  2. Jackson R, Lawes CMM, Bennett DA. Treatment with drugs to lower blood pressure and blood cholesterol based on an indyviduals absolute cardiovascular risk. Lancet. 2005; 365(9457): 434–441.
  3. Opie L. Blood Pressure Lowering Treatment Trialists' Collaboration.. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014; 384(9943): 591–598.
  4. Ettehad D, Emdin CA, Kiran A. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957–967.
  5. Mihaylova B, Emberson J, Blackwell L. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841): 581–590.
  6. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014; 64(20): 2071–2082.
  7. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
  8. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
  9. Sever PS, Poulter NR. Management of hypertension: is it the pressure or the drug? Blood pressure reduction is not the only determinant of outcome. Circulation. 2006; 113(23): 2754–2774.
  10. Staessen JA, Thijs L, Li Y, et al. Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs. Curr Opin Cardiol. 2007; 22(4): 335–343.
  11. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113(9): 1213–1225.
  12. Tykarski A, Grajek S. Badanie CAFE — komentarz. Nadciśnienie Tętnicze. 2006; 10: 411.
  13. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000; 102(13): 1503–1510.
  14. Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292(18): 2217–2225.
  15. Lüscher TF, Pieper M, Tendera M, et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J. 2009; 30(13): 1590–1597.
  16. Mehlum M, Liestøl K, Julius S, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426): 2022–2031.
  17. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23): 2417–2428.
  18. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290(21): 2805–2816.
  19. Grajek S. The landscape after PEACE: do all ACE inhibitors act in an identical way? Curr Med Res Opin. 2006; 22(2): 265–274.
  20. Bruining N, de Winter S, Roelandt JR, et al. EUROPA/PERSPECTIVE Investigators. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis. 2009; 20(6): 409–414.
  21. Zhuo JL, Mendelsohn F, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002; 39(2): 634–638.
  22. Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009; 30(11): 1385–1394.
  23. Neal B, Turnbull F, Neal B, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007; 25(5): 951–958.
  24. Verdecchia P, Angeli F, Cavallini C, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005; 46(2): 386–392.
  25. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011; 305(9): 913–922.
  26. van Vark LC, Bertrand M, Akkerhuis K KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16): 2088–2097.
  27. Bertrand ME, Ferrari R, Remme WJ, et al. EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010; 159(5): 795–802.
  28. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364): 1149–1158.
  29. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14): 1425–1435.
  30. Kostis JB, Breazna A, Deedwania PC, et al. Treating to New Targets Steering Committee and Investigators. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. J Clin Hypertens (Greenwich). 2008; 10(5): 367–376.
  31. Bangalore S, Fayyad R, Laskey R, et al. Treating to New Targets Steering Committee and Investigators. Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. Eur Heart J. 2014; 35(27): 1801–1808.
  32. Piepoli MF, Hoes A, Agewall S, et al. Wytyczne ESC dotyczące prewencji chorób układu sercowo-naczyniowego w praktyce klinicznej w 2016 roku. Kardiol Pol. 2016; 74(9): 821–936.
  33. Ridker PM, Danielson E, Fonseca FAH, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21): 2195–2207.
  34. Hsia J, MacFadyen J, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. J Am Coll Cardiol. 2011; 57(16): 1666–1675.
  35. Williams B, Lacy PS, Cruickshank JK, et al. CAFE and ASCOT Investigators. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation. 2009; 119(1): 53–61.
  36. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal. 2006; 27(24): 2982–2988.
  37. Bertrand ME, Vlachopoulos C, Mourad JJ. Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. Am J Cardiovasc Drugs. 2016; 16(4): 241–253.
  38. Fox KM, Bertrand ME, Remme WJ, et al. EUROPA Investigators. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J. 2007; 153(4): 629–635.
  39. Hoang Vu, Alam M, Addison D, et al. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern statin rra: a meta-analysis of randomized-controlled trials. Cardiovasc Drugs Ther. 2016; 30(2): 189–198.
  40. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2017; pii: S0735-1097(17): 41519–1.
  41. Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol. 2017; 70(24): 2979–2991.
  42. Heller DJ, Coxson PG, Penko J, et al. Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke. Circulation. 2017; 136(12): 1087–1098.
  43. Hayward RA. When to start a statin is a preference-sensitive decision. Circulation. 2017; 136(12): 1099–1101.
  44. Tsujita K, Sugiyama S, Sumida H, et al. PRECISE–IVUS Investigators. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronaryintervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015; 66(5): 495–507.
  45. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459–2472.
  46. Ueda H, Harimoto K, Tomoyama S, et al. Association between cardiovascular risk factors and the presence of coronary plaque in a zero or low coronary artery calcium score. Int J Cardiol. 2011; 147(3): 475–477.
  47. Nicholls SJ, Tuzcu EM, Wolski K, et al. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol. 2007; 49(2): 263–270.
  48. Tykarski A, Narkiewicz K, Gaciong Z, et al. Zasady postępowania w nadciśnieniu tętniczym — 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego — wersja skrócona. Kardiol Pol. 2015; 73(8): 676–700.
  49. Blacher J, Evans A, Arveiler D, et al. PRIME Study Group. Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study. J Hypertens. 2004; 22(2): 415–423.
  50. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388(10059): 2532–2561.
  51. Giugliano RP, Pedersen TR, Park JG, et al. FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390(10106): 1962–1971.
  52. Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Pharm Assoc (2003). 2013 [Epub ahead of print]; 63(25 Pt B): e1–2934.
  53. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147–1152.
  54. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008; 336(7653): 1114–1117.
  55. Cilla DD, Gibson D, Whitfield L, et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 2013; 36(7): 604–609.
  56. de Zeeuw D, Anzalone DA, Cain VA VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3(3): 181–190.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k. ul. Świętokrzyska 73, 80–180 Gdańsk

tel.: +48 58 320 94 94, faks:+48 58 320 94 60,  e-mail: viamedica@viamedica.pl